Guggenheim Upgrades Enliven Therapeutics (NASDAQ:ELVN) to Strong-Buy

Enliven Therapeutics (NASDAQ:ELVN) was upgraded by equities researchers at Guggenheim to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

ELVN has been the topic of a number of other research reports. HC Wainwright increased their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Mizuho raised their price objective on Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. The Goldman Sachs Group raised their target price on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Enliven Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $53.17.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $42.30 on Monday. The company has a market cap of $2.58 billion, a P/E ratio of -25.33 and a beta of 0.32. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $48.53. The stock’s fifty day moving average price is $37.73 and its two-hundred day moving average price is $27.75.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. On average, analysts expect that Enliven Therapeutics will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Enliven Therapeutics

In related news, Director Richard A. Heyman sold 1,230 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the completion of the sale, the director owned 22,647 shares of the company’s stock, valued at $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the sale, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at $1,508,580. This trade represents a 16.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 25.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP grew its position in Enliven Therapeutics by 70.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 681,715 shares of the company’s stock worth $26,714,000 after purchasing an additional 282,822 shares during the period. KBC Group NV bought a new position in Enliven Therapeutics in the 1st quarter worth $38,000. Jennison Associates LLC bought a new position in Enliven Therapeutics in the 1st quarter worth $12,120,000. Bank of New York Mellon Corp boosted its holdings in Enliven Therapeutics by 8.6% in the 1st quarter. Bank of New York Mellon Corp now owns 120,057 shares of the company’s stock worth $4,706,000 after buying an additional 9,488 shares during the period. Finally, Candriam S.C.A. boosted its holdings in Enliven Therapeutics by 31.1% in the 1st quarter. Candriam S.C.A. now owns 594,079 shares of the company’s stock worth $23,288,000 after buying an additional 141,060 shares during the period. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.